166 related articles for article (PubMed ID: 37946262)
1. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA.
Jodele S; Dandoy CE; Aguayo-Hiraldo P; Lane A; Teusink-Cross A; Sabulski A; Mizuno K; Laskin BL; Freedman J; Davies SM
Blood; 2024 Mar; 143(12):1112-1123. PubMed ID: 37946262
[TBL] [Abstract][Full Text] [Related]
2. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
3. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
4. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
5. Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation.
El-Bietar J; Warren M; Dandoy C; Myers KC; Lane A; Wallace G; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1994-2001. PubMed ID: 26150023
[TBL] [Abstract][Full Text] [Related]
6. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
7. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
9. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
10. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic microangiopathy - the importance of a multidisciplinary approach.
Tran MH; Patel S; Desai S; Ciurea S; Lee BJ; Hanna R
Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):247-256. PubMed ID: 38018789
[TBL] [Abstract][Full Text] [Related]
12. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy.
Gomez-Ganda L; Benitez-Carabante MI; Fernandez-Polo A; Muñoz-Lopez M; Renedo-Miro B; Ariceta G; Diaz De Heredia C
Front Pediatr; 2021; 9():761726. PubMed ID: 34858907
[No Abstract] [Full Text] [Related]
13. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.
Mizuno K; Dandoy CE; Teusink-Cross A; Davies SM; Vinks AA; Jodele S
Blood Adv; 2022 Mar; 6(5):1454-1463. PubMed ID: 35008105
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.
Shimizu S; Morohashi T; Kanezawa K; Yagasaki H; Takahashi S; Morioka I
Front Pediatr; 2022; 10():908183. PubMed ID: 35859949
[TBL] [Abstract][Full Text] [Related]
16. Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim.
Awidi M; Jain M; Baur R
Eur J Case Rep Intern Med; 2021; 8(3):002294. PubMed ID: 33768076
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy.
Schoettler ML; Saldana BD; Berkenkamp L; Chonat S; Watkins B; Rotz SJ; Simons D; Graf E; Rossi C; Cheng J; Hammers YA; Rytting H; Williams KM
Transplant Cell Ther; 2023 Jan; 29(1):45.e1-45.e8. PubMed ID: 36202334
[TBL] [Abstract][Full Text] [Related]
18. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study.
Svec P; Elfeky R; Galimard JE; Higham CS; Dalissier A; Quigg TC; Bueno Sanchez D; Han Lum S; Faraci M; Cole T; Pichler H; Benítez-Carabante MI; Horakova J; Gonzalez-Vicent M; Yanir A; Fagioli F; Wölfl M; von der Weid N; Protheroe R; Krivan G; Speckmann C; James B; Avcin SL; Bertrand Y; Verna M; Riha P; Patrick K; Cesaro S; Kalwak K; Bierings M; Büchner J; Mellgren K; Prohászka Z; Neven B; Lankester A; Corbacioglu S
Bone Marrow Transplant; 2023 Feb; 58(2):129-141. PubMed ID: 36333550
[TBL] [Abstract][Full Text] [Related]
19. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.
Jodele S; Sabulski A
Expert Rev Hematol; 2021 Aug; 14(8):751-763. PubMed ID: 34301169
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
